Normunity
Melinda Merchant has extensive work experience in the field of clinical development and medical affairs. Melinda currently holds the position of Senior Vice President of Clinical Development at Normunity, a role they have held since September 2022. Prior to this, they served as the VP of Clinical Development & Medical Affairs at Black Diamond Therapeutics from May 2021 to September 2022.
Before joining Black Diamond Therapeutics, Melinda worked at Epizyme as the VP of Early Stage Development from August 2019 to April 2021. Melinda also served as a Senior Medical Director at AstraZeneca from August 2015 to August 2019.
Melinda's career started at the National Institutes of Health in 2009, where they worked as a Pediatric Oncologist until August 2015. Prior to that, they held the position of Assistant Member at the Memorial Sloan-Kettering Cancer Center from 2005 to 2009. Melinda began their medical career as a Pediatric Resident at Children's National Medical Center from 1996 to 1999.
Melinda Merchant has attended Houghton University, but the specific start and end years are unknown. Melinda then pursued a MD, PhD degree at the University of Miami School of Medicine. Again, the duration of their studies at this institution is unspecified.
This person is not in any teams
This person is not in any offices
Normunity
1 followers
Normunity is a biotechnology company creating a new class of precision immuno-oncology medicines, called immune normalizers, that target novel mechanisms that free the body’s normal immunity against cancer.Based on an ongoing, interactive academic-biotech alliance with the lab of Dr. Lieping Chen at Yale School of Medicine, Normunity is targetingnewly-discovered mechanisms of immune disruption in cancer based on proprietary discovery platforms that elucidate the complex interactions between human cancer and the immune system. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer.Normunity is located in Boston, Massachusetts and West Haven, Connecticut.